Daratumumab at home for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if people with multiple myeloma can safely give themselves a medication called daratumumab under the skin at home, instead of going to the hospital for every dose. It aims to see if home self-administration is practical and acceptable for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma.
- You are starting or already using daratumumab as a shot under the skin.
- You can read and understand Danish.
- Your doctor agrees you are well enough to give yourself the medicine at home.
- You are willing to fill out questionnaires and talk with the study team.
- You do not live on an island without a bridge to the mainland.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if people with relapsed multiple myeloma can safely give themselves a medicine called elranatamab at home. It aims to make treatment more convenient while still being safe and effective.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a new pump system (FreedomEDGE®) to give daratumumab as a shot under the skin instead of the usual manual injection. It's for people with multiple myeloma or light chain amyloidosis who are already having daratumumab injections once a month.
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
This trial is for people with multiple myeloma who have already completed 12 cycles of a standard treatment (daratumumab, lenalidomide, and dexamethasone) and are doing well. It tests whether taking a break from treatment is safe and effective, instead of continuing without a break.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.